CN103536603B - 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 - Google Patents
一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 Download PDFInfo
- Publication number
- CN103536603B CN103536603B CN201310529812.0A CN201310529812A CN103536603B CN 103536603 B CN103536603 B CN 103536603B CN 201310529812 A CN201310529812 A CN 201310529812A CN 103536603 B CN103536603 B CN 103536603B
- Authority
- CN
- China
- Prior art keywords
- sulfamonomethoxine
- wettability
- powder
- sodium
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 220
- WMPXPUYPYQKQCX-UHFFFAOYSA-N Sulfamonomethoxine Chemical compound C1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 WMPXPUYPYQKQCX-UHFFFAOYSA-N 0.000 title claims abstract description 159
- 229950003874 sulfamonomethoxine Drugs 0.000 title claims abstract description 158
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract description 74
- 229910052708 sodium Inorganic materials 0.000 title abstract description 74
- 239000011734 sodium Substances 0.000 title abstract description 74
- IZJAOWYNDLDRKM-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-methoxypyrimidin-4-yl)azanide Chemical compound [Na+].C1=NC(OC)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 IZJAOWYNDLDRKM-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000000375 suspending agent Substances 0.000 claims abstract description 11
- 239000000080 wetting agent Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 49
- 239000012467 final product Substances 0.000 claims description 10
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 10
- 229960001082 trimethoprim Drugs 0.000 claims description 9
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 229940085605 saccharin sodium Drugs 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004384 Neotame Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 36
- 241001465754 Metazoa Species 0.000 abstract description 35
- 239000003814 drug Substances 0.000 abstract description 32
- 239000002131 composite material Substances 0.000 abstract description 19
- 230000009286 beneficial effect Effects 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 14
- 231100000331 toxic Toxicity 0.000 abstract description 13
- 230000002588 toxic effect Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 239000004615 ingredient Substances 0.000 abstract description 7
- 239000001508 potassium citrate Substances 0.000 abstract description 6
- 229960002635 potassium citrate Drugs 0.000 abstract description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 abstract description 6
- 235000011082 potassium citrates Nutrition 0.000 abstract description 6
- 241000282898 Sus scrofa Species 0.000 description 52
- 238000004806 packaging method and process Methods 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 206010028470 Mycoplasma infections Diseases 0.000 description 21
- 239000003651 drinking water Substances 0.000 description 20
- 235000020188 drinking water Nutrition 0.000 description 20
- 235000019629 palatability Nutrition 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000004062 sedimentation Methods 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 235000013330 chicken meat Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 238000013441 quality evaluation Methods 0.000 description 7
- 239000000273 veterinary drug Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 208000003495 Coccidiosis Diseases 0.000 description 5
- 206010023076 Isosporiasis Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002423 protozoacide Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010039088 Rhinitis atrophic Diseases 0.000 description 3
- 201000005485 Toxoplasmosis Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000014860 sensory perception of taste Effects 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- -1 Ds36 Chemical compound 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000009246 food effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000009318 large scale farming Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 201000006509 pleuropneumonia Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- QRJNBPKOGLCCKP-UHFFFAOYSA-N CN(C)C=1C(NC=CC1)=CC1=CC=CC=C1 Chemical compound CN(C)C=1C(NC=CC1)=CC1=CC=CC=C1 QRJNBPKOGLCCKP-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011509 Crystalluria Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960001887 aminometradine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940041003 long-acting sulfonamides Drugs 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
评价等级 | 评价标准 |
优 | 提供加药的饮水时,猪群受气味诱导,主动争抢饮用。 |
良 | 提供加药的饮水时,猪群按日常饮水习惯饮用。 |
差 | 提供加药的饮水时,猪群拒绝饮用或相对平常饮用量下降。 |
治疗效果 | 判定指标 |
痊愈 | 用药5天后,精神食欲恢复正常,临床症状消失。 |
显效 | 用药5天后,精神食欲好转,临床症状消失或减轻。 |
无效 | 用药5天后,症状无明显改善。 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529812.0A CN103536603B (zh) | 2013-10-31 | 2013-10-31 | 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529812.0A CN103536603B (zh) | 2013-10-31 | 2013-10-31 | 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103536603A CN103536603A (zh) | 2014-01-29 |
CN103536603B true CN103536603B (zh) | 2015-10-28 |
Family
ID=49960718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310529812.0A Active CN103536603B (zh) | 2013-10-31 | 2013-10-31 | 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103536603B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105343882B (zh) * | 2015-11-19 | 2019-01-25 | 河北普德动物药业有限公司 | 一种氟苯尼考增效可湿性粉剂及其制备方法 |
CN109248147A (zh) * | 2018-11-13 | 2019-01-22 | 镇江威特药业有限责任公司 | 一种可溶性奥美普林固体分散体及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1907264A (zh) * | 2006-08-04 | 2007-02-07 | 苏州科牧动物药品有限公司 | 复方磺胺混悬剂及其制备方法 |
CN101450055A (zh) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | 一种用于治疗畜禽细菌感染及寄生虫病的可溶性粉 |
-
2013
- 2013-10-31 CN CN201310529812.0A patent/CN103536603B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1907264A (zh) * | 2006-08-04 | 2007-02-07 | 苏州科牧动物药品有限公司 | 复方磺胺混悬剂及其制备方法 |
CN101450055A (zh) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | 一种用于治疗畜禽细菌感染及寄生虫病的可溶性粉 |
Non-Patent Citations (1)
Title |
---|
沈晋良.可湿性粉剂.《农药加工与管理》.中国农业出版社,2002,(第1版),96-98. * |
Also Published As
Publication number | Publication date |
---|---|
CN103536603A (zh) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103054808B (zh) | 一种替米考星干混悬剂及其制备方法和用途 | |
CN104068306B (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CN101496811B (zh) | 一种可溶且稳定的替米考星组合物 | |
CN104688683A (zh) | 一种阿苯达唑混悬剂及其制备方法 | |
RU2428187C2 (ru) | Средство против вируса ящура для животных, относящихся к семейству свиней или овец, и способы профилактики и лечения ящура у животных, относящихся к семейству свиней или овец | |
CN111700874A (zh) | 一种恩诺沙星肠溶速释掩味颗粒剂及其制备方法 | |
CN103536603B (zh) | 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 | |
CN102772363A (zh) | 一种含泊那珠利的溶液剂及其制备方法 | |
CN103536604B (zh) | 一种可湿性联磺甲氧苄啶粉及其制备方法 | |
CN101209296A (zh) | 一种具有驱虫保肝、止血止痢功效的中药颗粒剂 | |
CN107595871A (zh) | 含伊维菌素复方制剂及其制备方法 | |
CN102145011B (zh) | 一种防治腹泻的组合物及其制备方法和应用 | |
CN103520267A (zh) | 一种可湿性止痢散及其制备方法 | |
CN103536606B (zh) | 一种可湿性磺胺对甲氧嘧啶粉及其制备方法 | |
CN102379920B (zh) | 一种兽用抗病毒退热药物组合物 | |
CN101953871B (zh) | 一种动物用抗菌药物及其制备方法和应用 | |
CN112826797A (zh) | 一种新型复方抗球虫可溶性粉及其制备方法 | |
CN103690546B (zh) | 一种猫用预防和治疗弓形虫病的口腔崩解片及其制备方法 | |
US10426840B2 (en) | Oil suspension of metronidazole | |
WO2010013129A1 (es) | Combinación coccidicida para uso veterinario | |
CN101904858A (zh) | 一种抗球虫混悬剂的制备方法 | |
CN103623019B (zh) | 一种可湿性穿心莲固体分散粉及其制备方法 | |
CN104706701B (zh) | 一种中西复方药物组合物及其制备方法和应用 | |
CN102000100A (zh) | 一种抗球虫的纳米混悬剂及其配制方法 | |
CN105311007B (zh) | 苏拉明钠在制备抗鸡球虫药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 259, Middle Section of Jinfu Road, Wenjiang District, Chengdu City, Sichuan Province, 611130 Patentee after: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL CO.,LTD. Patentee after: SHANGHAI SIMENON BIOTECHNOLOGY Co.,Ltd. Address before: No. 259 Jinfu Road, Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611137 Patentee before: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI SIMENON BIOTECHNOLOGY Co.,Ltd. |